Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review
The Prostate · 2025
DOI: 10.1002/pros.24890 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Prostate, 2025. Verfasst von Mark Willy L Mondia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuro-Oncology, Department of Neurology, University of Virginia, Charlottesville, Virginia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Brain Neoplasms, Magnetic Resonance Imaging. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Brain metastases (BMETS) from prostate cancer are rare. Hence, brain imaging in neurologically asymptomatic patients with advanced prostate cancer (aPC) is not routinely performed. Prostate‐specific membrane antigen (PSMA) PET/CT uses a radiotracer that binds to prostate cancer epithelial cells and is FDA‐approved for initial staging for high‐risk prostate cancer, detecting prostate cancer recurrence, and determining eligibility for radionuclide therapy.
Methods
We report six patients with asymptomatic BMETS from aPC found on staging PSMA PET/CT or MRI. Along with cranial MRI, PSMA PET/CT may be useful for detecting asymptomatic intracranial metastasis in select patients with prostate cancer.
Results
Brain metastases were diagnosed in four patients by staging PSMA PET/CT scan—three after systemic disease progression and one during routine surveillance. In two other patients, BMETS were detected using MRI despite negative PSMA PET/CT for brain lesions. All were neurologically asymptomatic. Three patients had undetectable serum prostate‐specific antigen (PSA) concentrations; one had neuroendocrine differentiation on histology.
Conclusion
In patients with poorly differentiated or neuroendocrine aPC, BMETS may occur without neurologic symptoms and stable PSA. PSMA PET/CT may complement brain MRI for identifying BMETS in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neuro-Oncology, Department of Neurology, University of Virginia, Charlottesville, Virginia.
- Division of Nuclear Medicine, Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia.
- Division of Hematology/Oncology, Departments of Medicine and Urology, University of Virginia, Charlottesville, Virginia.
- Department of Pathology, University of Virginia, Charlottesville, Virginia.
- Department of Neurosurgery, University of Virginia, Charlottesville, Virginia.
ORCID-Profile: Mark Willy L Mondia, Camilo E Fadul
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Mondia, M. W. L., Batchala, P. P., Dreicer, R., Devitt, M. E., McCord, M. R., Mut, M., Sheehan, J. P., Schiff, D., & Fadul, C. E. (2025). Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review. The Prostate. https://doi.org/10.1002/pros.24890
Vancouver
Mondia MWL, Batchala PP, Dreicer R, Devitt ME, McCord MR, Mut M, et al. Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review. The Prostate. 2025. doi:10.1002/pros.24890
BibTeX
@article{Mondia2025,
author = {Mondia, Mark Willy L and Batchala, Prem P and Dreicer, Robert and Devitt, Michael E and McCord, Matthew R and Mut, Melike and Sheehan, Jason P and Schiff, David and Fadul, Camilo E},
title = {Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24890}
}
EUVIMED